<DOC>
	<DOCNO>NCT02080520</DOCNO>
	<brief_summary>The potential nattokinase `` thin '' blood reduce blood clot positive antithrombotic fibrinolytic effect present unique opportunity safely study effect cardiovascular disease cognition . Unfortunately , study antithrombotic fibrinolytic pathway prevention limit due lack safe compound adverse reaction associate current agent Coumadin . Nattokinase , over-the-counter supplement use cardiovascular health , active functional constituent natto , ferment soy product . Natto consume primarily Japanese 1000 year , population one low risk cardiovascular disease dementia . Cardiovascular disease dementia remain challenge age-related health risk 21st century Americans necessitate development effective preemptive strategy . Whether reduce propensity thrombus formation and/or increase fibrinolytic activity prevent progression atherosclerosis cognitive decline yet determine . Using nattokinase primary prevention condition , investigator propose conduct randomize , double-blinded , placebo-controlled trial determine whether decrease atherothrombotic risk reduce progression atherosclerosis cognitive decline . The investigator propose randomize 240 healthy non-demented woman men nattokinase supplementation placebo three year . The primary trial end point measurement carotid arterial wall thickness arterial stiffness , early change atherosclerosis measure safely non-invasive image technique . The secondary trial end point ascertain change cognition measure neuropsychological battery . In addition , biochemical blood measurement vitro study conduct compare effect nattokinase relative placebo blood coagulation thrombus break-down capability , blood flow property , inflammation inflammatory activation endothelial cell line blood vessel . At conclusion trial , investigator expect sufficient evidence whether reduce propensity thrombus formation and/or increase fibrinolytic activity prevent progression atherosclerosis cognitive decline . These result provide novel important data informative concern primary prevention atherothrombotic pathway . Providing evidence reduction atherosclerosis progression cognitive decline nattokinase likely shift current clinical paradigm prevention chronic age-related process . In addition , evidence serve create new field discovery opportunity prevention cardiovascular disease dementia .</brief_summary>
	<brief_title>Nattokinase Atherothrombotic Prevention Study</brief_title>
	<detailed_description>Objectives Hypotheses : The goal propose study determine randomize control trial ( RCT ) condition whether nattokinase reduces subclinical atherosclerosis cognitive decline healthy woman men . The investigator ' hypothesis : 1 ) Compared placebo , nattokinase show less subclinical atherosclerosis progression cognitive decline healthy woman men ; 2 ) The reduction subclinical atherosclerosis progression cognitive decline nattokinase correlate ; , 3 ) The reduction progression subclinical atherosclerosis cognitive decline nattokinase mediate hemostatic , fibrinolytic hemorheological factor well attenuation inflammation , monocyte activation , vascular endothelium injury activation vascular endothelium circulate monocyte . Specific Aims : To conduct RCT determine effect nattokinase progression subclinical atherosclerosis ( primary trial end point ) cognitive decline ( secondary trial end point ) . Healthy non-demented woman men &gt; 55 year old without pre-existing symptomatic CVD diabetes mellitus randomize 2 year period oral nattokinase ( 2,000 fibrinolysis unit ) daily versus placebo double-blind , placebo-controlled trial ; randomize treatment 3-years . The follow 5 major specific aim complete : 1 . To determine effect nattokinase progression subclinical carotid artery atherosclerosis determine rate change common carotid artery intima-media thickness ( CIMT ) arterial stiffness computer image process B-mode ultrasonograms . 2 . To determine effect nattokinase cognitive decline determine neuropsychological battery design evaluate 7 cognitive domain include : attention , concentration , work memory , executive function ; visuospatial/visuoconstructive skill ; naming/semantic memory ; verbal nonverbal episodic memory . 2a . To determine effect nattokinase cognitive decline accord apolipoprotein ( Apo ) E e4 genotype . 3 . To determine association subclinical atherosclerosis progression cognitive decline . 4 . To determine whether effect nattokinase subclinical atherosclerosis cognitive decline mediate hemostatic ( fibrinogen , factor VIII , platelet activity ) , fibrinolytic ( tPA , PAI-1 , D-dimer ) , hemorheological ( plasma blood viscosity , red blood cell aggregation ) inflammatory ( MCP-1 , IL-8 , TNFα , IL-1β , IL-10 , monocyte cell surface marker CD11b/CD11c VLA-4 , expression adhesion molecules VCAM-1 ICAM-1 culture human aortic endothelial cell ) factor well blood pressure .</detailed_description>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Age &gt; 55 year Male postmenopausal female ( uterine bleeding &gt; 6 month ) Clinical sign , symptom , personal history CVD Diabetes mellitus fast serum glucose &gt; 140 mg/dL Plasma triglyceride level &gt; 500 mg/dL Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 110 mmHg ) * Uncontrolled tachycardia irregular heart rate ( i.e. , atrial fibrillation ) Thyroid disease ( untreated ) Renal insufficiency ( define serum creatinine &gt; 2.0 mg/dL ) Life threaten illness prognosis &lt; 5 year Current use lipidlowering medication Current use food supplement contain soy , soy protein , isoflavones phytoestrogens Known sensitivity allergy soy nut Regular aspirin antiplatelet medication use Use anticoagulant Bleeding diatheses tendency</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Soy</keyword>
	<keyword>Fermented soy</keyword>
	<keyword>Nattokinase</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Carotid artery</keyword>
	<keyword>Cognition</keyword>
	<keyword>Atherothrombosis</keyword>
</DOC>